Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through
wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir …

Background: Combination ART (cART)-related toxicities and costs have prompted the need
for treatment simplification. The ATLAS-M trial explored 48 week non-inferior efficacy of …

Although HAART suppresses HIV replication, it is often unable to restore immune
homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated …

Dear Editor, In response to the COVID-19 pandemic, on 9 March 2020, the Italian
government announced a nationwide lockdown programme of social distancing …

Background. We evaluated reliability and clinical usefulness of genotypic resistance testing
(GRT) in patients for whom combination antiretroviral therapy (cART) was unsuccessful with …

BACKGROUND: Anal human papillomavirus (HPV) infection is very common in men having
sex with men (MSM), but the available data on its burden and characteristics mainly concern …

Data on COVID-19 boosting vaccination in people living with HIV (PLWH) are scant. We
investigated the immunogenicity and safety of the BNT162b2 homologous boosting …

Objectives The aim of the present study was to compare the efficacy and durability of
treatment switch to two‐drug (2DR) vs. three‐drug (3DR) integrase inhibitor (InSTI)‐based …

Despite the evidence emerged from phase III clinical trials [2], limited data support the use of
dolutegravir-based regimens in highly treatment-experienced, virologically suppressed …

Objectives To investigate the long-term safety and efficacy of a treatment switch to dual ART
with atazanavir/ritonavir+ lamivudine versus continuing a standard regimen with …